Collegium Pharmaceutical (COLL) Short-term Investments (2014 - 2026)

Collegium Pharmaceutical's Short-term Investments history runs 5 years deep, the most recent figure standing at $19.8 million for Q1 2026.

• On a quarterly basis, Short-term Investments fell 80.46% year-over-year to $19.8 million in Q1 2026; TTM through Mar 2026 was $19.8 million, a 80.46% decrease from a year earlier, with the FY2025 full-year figure at $19.8 million, down 78.47% from the prior year.
• Short-term Investments held at $19.8 million in Q1 2026 per COLL's latest filing, from $19.8 million in the prior quarter.
• Across five years, Short-term Investments topped out at $135.8 million in Q3 2025 and bottomed at $19.8 million in Q2 2025.
• The 4-year median for Short-term Investments is $76.3 million (2023), against an average of $68.1 million.
• Across the five-year window, Short-term Investments soared 136.66% in 2024 and tumbled 80.46% in 2026, its largest moves.
• Year by year, Short-term Investments stood at $71.6 million in 2023, then advanced by 28.77% to $92.2 million in 2024, then sank by 78.47% to $19.8 million in 2025, then changed by 0.0% to $19.8 million in 2026.
• Per Business Quant, the three latest COLL Short-term Investments figures stand at $19.8 million (Q1 2026), $19.8 million (Q4 2025), and $135.8 million (Q3 2025).